Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine.

Department of Biochemistry Faculty of Science Palacký University Olomouc Czechia

Department of Pharmacology and Toxicology Veterinary Research Institute Brno Czechia

Dyntec spol s r o Terezin Czechia

Faculty of Science Charles University Prague Czechia

Zobrazit více v PubMed

Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol. (1996) 8:484–91. 10.1016/S0952-7915(96)80035-5 PubMed DOI

Okabayashi M, Angell MG, Christensen ND, Kreider JW. Morphometric analysis and identification of infiltrating leucocytes in regressing and progressing shope rabbit papillomas. Int J Cancer. (1991) 49:919–23. 10.1002/ijc.2910490620 PubMed DOI

Campo MS ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. Wymondham: Caister Academic; (2006). p. 423.

Knottenbelt DC. A suggested clinical classification for the equine sarcoid. Clin Tech Equine Pract. (2005) 4:278–95. 10.1053/j.ctep.2005.10.008 DOI

Bertagnolli AC, Bezerra AVA, Santos RN, Cavalli LS, Varela APM, Reis EM, et al. . Clinicopathological characteristics and papillomavirus types in cutaneous warts in bovine. Braz J Microbiol. (2020) 51:395–401. 10.1007/s42770-019-00121-2 PubMed DOI PMC

Kaynarcalidan O, Oguzoglu TÇ. The oncogenic pathways of papillomaviruses. Vet Comp Oncol. (2021) 19:7–16. 10.1111/vco.12659 PubMed DOI

Yan D, Wei Y-Q, Guo H-C, Sun S-Q. The application of virus-like particles as vaccines and biological vehicles. Appl Microbiol Biotechnol. (2015) 99:10415–32. 10.1007/s00253-015-7000-8 PubMed DOI PMC

Araldi RP, Giovanni DNS, Melo TC, Diniz N, Mazzuchelli-de-Souza J, Sant'Ana TA, et al. . Bovine papillomavirus isolation by ultracentrifugation. J Virol Methods. (2014) 208:119–24. 10.1016/j.jviromet.2014.07.029 PubMed DOI

Shevchenko A, Tomas H, Havli J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. (2006) 1:2856–60. 10.1038/nprot.2006.468 PubMed DOI

Petrovská B, Jerábková H, Chamrád I, Vrána J, Lenobel R, Urinovská J, et al. . Proteomic analysis of barley cell nuclei purified by flow sorting. Cytogenet Genome Res. (2014) 143:78–86. 10.1159/000365311 PubMed DOI

Arnesen T. Towards a functional understanding of protein N-terminal acetylation. PLoS Biol. (2011) 9:e1001074. 10.1371/journal.pbio.1001074 PubMed DOI PMC

Wallace RJ. Acetylation of peptides inhibits their degradation by rumen micro-organisms. Br J Nutr. (1992) 68:365–72. 10.1079/BJN19920095 PubMed DOI

Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. . Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. (1996) 219:37–44. 10.1006/viro.1996.0220 PubMed DOI

Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol. (1997) 15:275–83. 10.1016/S0738-081X(96)00165-4 PubMed DOI

Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens. Res Vet Sci. (2012) 93:553–9. 10.1016/j.rvsc.2011.10.018 PubMed DOI

Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. (2008) 109:S15–21. 10.1016/j.ygyno.2008.02.003 PubMed DOI

Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol. (2016) 16:79–89. 10.1038/nri.2015.3 PubMed DOI

Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, et al. . Cellular immune responses to HPV-18,−31, and−53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology. (2006) 353:451–62. 10.1016/j.virol.2006.06.021 PubMed DOI

Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity. Nature. (2012) 483:227–31. 10.1038/nature10851 PubMed DOI PMC

Harnacker J, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Brandt S. Type-specific L1 virus-like particle-mediated protection of horses from experimental bovine papillomavirus 1-induced pseudo-sarcoid formation is long-lasting. J Gen Virol. (2017) 98:1329–33. 10.1099/jgv.0.000791 PubMed DOI

Jagu S, Malandro N, Kwak K, Yuan H, Schlegel R, Palmer KE, et al. . A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology. (2011) 420:43–50. 10.1016/j.virol.2011.07.020 PubMed DOI PMC

Módolo DG, Araldi RP, Mazzuchelli-de-Souza J, Pereira A, Pimenta DC, Zanphorlin LM, et al. . Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine. Vaccine. (2017) 35:1590–3. 10.1016/j.vaccine.2017.02.007 PubMed DOI

Jesus ALS, Mariz FC, Souza HM, Cordeiro MN, Coimbra EC, Leitão MCG, et al. . Expression of the bovine papillomavirus type 1, 2 and 4 L1 genes in the yeast Pichia pastoris. Genet Mol Res. (2012) 11:2598–607. 10.4238/2012.July.19.2 PubMed DOI

Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. (1992) 89:12180–4. 10.1073/pnas.89.24.12180 PubMed DOI PMC

Love AJ, Chapman SN, Matic S, Noris E, Lomonossoff GP, Taliansky M. In planta production of a candidate vaccine against bovine papillomavirus type 1. Planta. (2012) 236:1305–13. 10.1007/s00425-012-1692-0 PubMed DOI

Huhti L, Blazevic V, Nurminen K, Koho T, Hytönen VP, Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol. (2010) 155:1855–8. 10.1007/s00705-010-0768-z PubMed DOI PMC

Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. . Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. (1995) 92:11553–7. 10.1073/pnas.92.25.11553 PubMed DOI PMC

Hainisch EK, Brandt S, Shafti-Keramat S, Van Den Hoven R, Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses: VLP-based sarcoid prophylaxis. Equine Vet J. (2012) 44:107–11. 10.1111/j.2042-3306.2011.00390.x PubMed DOI PMC

Lima TM, Souza MO, Castilho LR. Purification of flavivirus VLPs by a two-step chomatographic process. Vaccine. (2019) 37:7061–9. 10.1016/j.vaccine.2019.05.066 PubMed DOI

Yang D, Chen L, Duan J, Yu Y, Zhou J, Lu H. Investigation of Kluyveromyces marxianus as a novel host for large-scale production of porcine parvovirus virus-like particles. Microb Cell Fact.(2021) 20:24. 10.1186/s12934-021-01514-5 PubMed DOI PMC

Roder C, Krusat T, Reimers K, Werchau H. Purification of respiratory syncytial virus F and G proteins. J Chromatogr B Biomed Sci App. (2000) 737:97–106. 10.1016/S0378-4347(99)00442-9 PubMed DOI